-
公开(公告)号：US20160289185A1
公开(公告)日：2016-10-06
申请号：US15036211
申请日：2014-11-14
发明人： TROY E. MESSICK , GARRY R. SMITH , ALLEN B. REITZ , PAUL M. LIEBERMAN , MARK E. McDONNELL , YAN ZHANG , VENKATA VELVADAPU
IPC分类号： C07D207/327 , C07D471/04 , C07D401/10 , C07D487/04 , C07D409/10 , C07D417/10 , C07C53/18 , C07D209/08 , C07C229/64 , C07C229/56 , C07C65/19 , C07D277/30 , C07D213/55 , C07C63/66 , C07C65/28 , C07D211/70 , C07C317/44 , C07D231/12 , C07D239/26 , C07D207/08 , C07D207/14 , C07D207/16 , C07D207/12 , C07D295/155 , C07D249/06 , C07D401/04 , C07D215/14 , C07D213/64 , C07D213/74 , C07D307/79 , C07D333/54 , C07D403/10
CPC分类号： C07D207/327 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C211/27 , C07C217/84 , C07C229/56 , C07C229/64 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C255/54 , C07C255/55 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07C317/44 , C07C2601/02 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D209/08 , C07D211/70 , C07D213/55 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D235/06 , C07D239/26 , C07D249/06 , C07D277/30 , C07D295/155 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10 , C07D403/10 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04
摘要： The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.
摘要翻译： 本发明提供了EBNA1抑制剂和包含其的药物组合物，其可用于治疗由EBNA1活性引起的疾病，例如但不限于癌症，感染性单核细胞增多症，慢性疲劳综合征，多发性硬化症，系统性红斑狼疮和/ 或类风湿性关节炎。 本发明的化合物和组合物还可用于治疗潜伏性EB病毒（EBV）感染引起的疾病。 本发明的化合物和组合物还可用于治疗由溶血性EBV感染引起的疾病。
-
公开(公告)号：US20180086699A1
公开(公告)日：2018-03-29
申请号：US15814600
申请日：2017-11-16
发明人： TROY E. MESSICK , GARRY R. SMITH , ALLEN B. REITZ , PAUL M. LIEBERMAN , MARK E. McDONNELL , YAN ZHANG , VENKATA VELVADAPU
IPC分类号： C07D207/327 , C07C311/08 , C07D207/16 , C07D211/70 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D249/06 , C07D277/30 , C07D307/79 , C07D333/54 , C07D401/04 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C229/64 , C07C317/44 , C07D207/08 , C07D401/10 , C07D207/14 , C07D213/55 , C07D295/155 , C07D209/08 , C07D487/04 , C07D471/04 , C07D417/10 , C07D409/10 , C07D239/26 , C07D403/10 , C07D235/06 , C07C229/56 , C07C235/58 , C07C233/65 , C07C233/64 , C07C233/11 , C07C217/84 , C07C211/27 , C07C255/55 , C07C255/54 , C07C317/14 , C07C311/17 , C07C311/16 , C07D207/12
摘要： Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
-
搜索结果
2 条记录 (耗时 0.02 秒)
